Acta Medica Nagasakiensia
Print ISSN : 0001-6055
Age, Symptomatic Metastatic Disease, and Malignant Pleural Effusion as Predictors of Poor Prognosis in Patients with Differentiated Thyroid Carcinoma Treated with Lenvatinib.
Yomi Nakashima , M.D.Takao Ando , M.D., Ph.D.Aya Nozaki , M.D., Ph.D.Ayako Ito , M.D.Ichiro Horie , M.D., Ph.D.Misa Imaizumi , M.D., Ph.D.Toshiro Usa , M.D., Ph.D.Atsushi Kawakami , M.D., Ph.D.
Author information

2020 Volume 63 Issue 2 Pages 71-77


Background: Lenvatinib is one of the few therapeutic options available for radioiodine-refractory thyroid cancer. However, the factors that determine the therapeutic outcomes remain unknown. Methods: Patients with thyroid carcinoma treated with lenvatinib who had been dead or who had survived for longer than a halfyear were retrospectively compared. We evaluated the clinical parameters when lenvatinib was started, and also studied the tumor volume reduction ratio, the duration until re-growth of the largest metastatic lesion, the thyroglobulin (Tg) reduction rate, and the duration until re-elevation of Tg after lenvatinib between survivors and dead patients. Results: We identified 16 patients, with an average age of 73.1±7.6 yrs and a male-to-female ratio of 5 to 11, who had advanced differentiated thyroid cancer that was treated with lenvatinib. Nine patients had died after 8.9±6.1 months, whereas 7 survived for 13.0±2.0 months after starting lenvatinib. The patients who died were older than the survivors (76.7±6.5 vs. 68.6±6.6 yrs, p=0.03). Malignant pleural effusion (p=0.017) and symptomatic metastatic disease (SMD) (p=0.039) were associated with death in a Kaplan-Meier survival analysis. Age (p=0.012, HR 1.150, CI 1.030-1.320) and SMD (p=0.014, HR 8.069, CI 1.503-61.34) were associated with poor outcome in a multivariate Cox proportional hazard model. The duration until the re-elevation of Tg was longer in survivors than in patients who died (6.43±4.55 vs. 2.17±1.39 months, p=0.025). Conclusions: We identified multiple factors, including SMD, that were related to poor outcomes after lenvatinib treatment. This study suggests that lenvatinib might be started before patients develop SMD.

Information related to the author
© 2020 by Nagasaki University School of Medicine
Previous article Next article